The article discusses various updates in the biotech industry. Monte Rosa Therapeutics signed a licensing deal with Novartis for an experimental drug, while AbbVie acquired Aliada Therapeutics for Alzheimer’s disease drugs. David Epstein, former CEO of Seagen, launched a new cancer startup called Ottimo Pharma. A feud between gene-editing companies Prime Medicine and Tessera Therapeutics is heating up. Patient advocates raised concerns about Merck’s drug posaconazole for cancer patients. The ethics of using early Alzheimer’s blood tests are also debated. Pfizer’s stock is predicted to remain strong despite activist battles. Revolution Medicines is making progress in treating pancreatic cancer. The FDA approved Iterum’s treatment for urinary infections.
Source link
Seagen, Merck, Prime, Alzheimer’s blood tests news
